Nilanjan Ghosh Dastidar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nilanjan Ghosh Dastidar has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Ana C. de A. P. Schwarzer
Project Group Molecular Machines in Motion, Department for Physical Biochemistry, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany
3 shared publications - Henning Urlaub
Department of Clinical Chemistry, University Medical Center Göttingen, Göttingen, Germany
3 shared publications - Ingo Wohlgemuth
Project Group Fidelity of Protein Synthesis in vivo, Department for Physical Biochemistry, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany
3 shared publications - Nicola S. Freyer
Department for Physical Biochemistry, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany
3 shared publications - Valentyn Petrychenko
Project Group Molecular Machines in Motion, Department of Physical Biochemistry, Max Planck Institute for Multidisciplinary Sciences, Goettingen, Germany
3 shared publications - Antonio Zaccaria Politi
Facility for Light Microscopy Max Planck Institute of Multidisciplinary Sciences Göttingen Germany
2 shared publications
Latest Publications
- Open Access
- 29 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Selective silencing of antibiotic-tethered ribosomes as a resistance mechanism against aminoglycosides
Antibiotic resistance is a growing threat, underscoring the need to understand the underlying mechanisms. Aminoglycosides kill bacteria by disrupting translation fidelity, leading to the synthesis of aberrant proteins. Surprisingly, mutations in fusA , a gene encoding translation elongation factor G (EF-G), frequently confer resistance, even though EF-G neither participates in mRNA decoding nor blocks aminoglycoside binding. Here, we show that EF-G resistance variants selectively slow ribosome movement along mRNA when aminoglycosides are bound. This delay increases the chance that the drug dissociates before misreading occurs. Over several elongation cycles, this selective silencing of drug-bound ribosomes prevents error cluster formation, preserving proteome and membrane integrity. As a result, fusA mutations confer resistance early in treatment by preventing self-promoted aminoglycoside uptake. Translation on drug-free ribosomes remains sufficiently rapid to sustain near-normal bacterial growth. The mechanism of selective silencing of corrupted targets reveals a previously unrecognized antibiotic resistance strategy with potential therapeutic implications.
- 29 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Open AccessSelective silencing of antibiotic-tethered ribosomes as a resistance mechanism against aminoglycosides
Antibiotic resistance is a growing threat, underscoring the need to understand the underlying mechanisms. Aminoglycosides kill bacteria by disrupting translation fidelity, leading to the synthesis of aberrant proteins. Surprisingly, mutations in fusA , a gene encoding translation elongation factor G (EF-G), frequently confer resistance, even though EF-G neither participates in mRNA decoding nor blocks aminoglycoside binding. Here, we show that EF-G resistance variants selectively slow ribosome movement along mRNA when aminoglycosides are bound. This delay increases the chance that the drug dissociates before misreading occurs. Over several elongation cycles, this selective silencing of drug-bound ribosomes prevents error cluster formation, preserving proteome and membrane integrity. As a result, fusA mutations confer resistance early in treatment by preventing self-promoted aminoglycoside uptake. Translation on drug-free ribosomes remains sufficiently rapid to sustain near-normal bacterial growth. The mechanism of selective silencing of corrupted targets reveals a previously unrecognized antibiotic resistance strategy with potential therapeutic implications.
- Open Access
- 27 October 2025
- Published by EMBL-EBI
Selective silencing of antibiotic-tethered ribosomes as a resistance mechanism against aminoglycosides
- 27 October 2025
- Published by EMBL-EBI
Open AccessSelective silencing of antibiotic-tethered ribosomes as a resistance mechanism against aminoglycosides
- Open Access
Selective silencing of antibiotic-tethered ribosomes as a resistance mechanism against aminoglycosides
Antibiotic resistance is a growing threat, underscoring the need to understand the underlying mechanisms. Aminoglycosides kill bacteria by disrupting translation fidelity, leading to the synthesis of aberrant proteins. Surprisingly, mutations in fusA , a gene encoding translation elongation factor G (EF-G), frequently confer resistance, even though EF-G neither participates in mRNA decoding nor blocks aminoglycoside binding. Here, we show that EF-G resistance variants selectively slow ribosome movement along mRNA when aminoglycosides are bound. This delay increases the chance that the drug dissociates before misreading occurs. Over several elongation cycles, this selective silencing of drug-bound ribosomes prevents error cluster formation, preserving proteome and membrane integrity. As a result, fusA mutations confer resistance early in treatment by preventing self-promoted aminoglycoside uptake. Translation on drug-free ribosomes remains sufficiently rapid to sustain near-normal bacterial growth. This previously unrecognized resistance mechanism— selective silencing of corrupted targets—reveals a novel antibiotic resistance strategy with potential therapeutic implications.
Open AccessSelective silencing of antibiotic-tethered ribosomes as a resistance mechanism against aminoglycosides
Antibiotic resistance is a growing threat, underscoring the need to understand the underlying mechanisms. Aminoglycosides kill bacteria by disrupting translation fidelity, leading to the synthesis of aberrant proteins. Surprisingly, mutations in fusA , a gene encoding translation elongation factor G (EF-G), frequently confer resistance, even though EF-G neither participates in mRNA decoding nor blocks aminoglycoside binding. Here, we show that EF-G resistance variants selectively slow ribosome movement along mRNA when aminoglycosides are bound. This delay increases the chance that the drug dissociates before misreading occurs. Over several elongation cycles, this selective silencing of drug-bound ribosomes prevents error cluster formation, preserving proteome and membrane integrity. As a result, fusA mutations confer resistance early in treatment by preventing self-promoted aminoglycoside uptake. Translation on drug-free ribosomes remains sufficiently rapid to sustain near-normal bacterial growth. This previously unrecognized resistance mechanism— selective silencing of corrupted targets—reveals a novel antibiotic resistance strategy with potential therapeutic implications.